HDL-C and Cardiovascular Risk: You Don't Need to Worry about Extremely High HDL-C Levels

키워드

참고문헌 (35)

1. Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
2. Adhyaru BB, "Safety and efficacy of statin therapy", Nat Rev Cardiol, 15, pp.757~769 (2018)
3. Kannel WB, "Risk factors in coronary heart disease. an evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study", Ann Intern Med, 61, pp.888~899 (1964)
4. Toth PP, "High-density lipoproteins : a consensus statement from the National Lipid Association", J Clin Lipidol, 7, pp.484~525 (2013)
5. Rader DJ, "HDL and cardiovascular disease", Lancet, 384, pp.618~625 (2014)
6. Castelli WP, "Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study", JAMA, 256, pp.2835~2838 (1986)
7. Ko DT, "High-density lipoprotein cholesterol and causespecific mortality in individuals without previous cardiovascular conditions : the CANHEART study", J Am Coll Cardiol, 68, pp.2073~2083 (2016)
8. Gordon DJ, "High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies", Circulation, 79, pp.8~15 (1989)
9. Frick MH, "Helsinki Heart Study : primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease", N Engl J Med, 317, pp.1237~1245 (1987)
10. AIM-HIGH InvestigatorsBoden WE, "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy", N Engl J Med, 365, pp.2255~2267 (2011)
11. Barter PJ, "Effects of torcetrapib in patients at high risk for coronary events", N Engl J Med, 357, pp.2109~2122 (2007)
12. Schwartz GG, "Rationale and design of the dal-OUTCOMES trial : efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome", Am Heart J, 158, pp.896~901 (2009)
13. Wilkins JT, "Coronary heart disease risks associated with high levels of HDL cholesterol", J Am Heart Assoc, 3, pp.e000519~ (2014)
14. Mackey RH, "High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events : MESA(multi-ethnic study of atherosclerosis)", J Am Coll Cardiol, 60, pp.508~516 (2012)
15. Madsen CM, "Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women : two prospective cohort studies", Eur Heart J, 38, pp.2478~2486 (2017)
16. 양여리, "High-Density Lipoprotein Cholesterol and the Risk of Myocardial Infarction, Stroke, and Cause-Specific Mortality: a Nationwide Cohort Study in Korea", 지질·동맥경화학회지, 10(1), pp.74~87 (2021), 한국지질동맥경화학회[DOI]
17. Oram JF, "ATP-binding cassette cholesterol transporters and cardiovascular disease", Circ Res, 99, pp.1031~1043 (2006)
18. Tall AR, "HDL, ABC transporters, and cholesterol efflux : implications for the treatment of atherosclerosis", Cell Metab, 7, pp.365~375 (2008)
19. Nissen SE, "Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes : a randomized controlled trial", JAMA, 290, pp.2292~2300 (2003)
20. Spencer RP, "Observations on lipids of the alimentary canal of the hagfish Eptatretus stoutii", Comp Biochem Physiol, 19, pp.139~144 (1966)
21. Nicholls SJ, "Will big data shine light at the end of the tunnel for HDL?", J Am Coll Cardiol, 68, pp.2084~2085 (2016)
22. Martin SS, "HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention : the Lipoprotein Investigators Collaborative", Eur Heart J, 36, pp.22~30 (2015)
23. Gebhard C, "HDL and cardiovascular risk : is cholesterol in particle subclasses relevant?", Eur Heart J, 36, pp.10~12 (2015)
24. Singh K, "Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk", J Thorac Dis, 10, pp.109~112 (2018)
25. Khetarpal SA, "Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterol", PLoS Genet, 7, pp.e1002393~ (2011)
26. Voight BF, "Plasma HDL cholesterol and risk of myocardial infarction : a mendelian randomisation study", Lancet, 380, pp.572~580 (2012)
27. Zanoni P, "Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease", Science, 351, pp.1166~1171 (2016)
28. Takeuchi F, "Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals", PLoS One, 7, pp.e46385~ (2012)
29. Millwood IY, "Association of CETP gene variants with risk for vascular and nonvascular diseases among Chinese adults", JAMA Cardiol, 3, pp.34~43 (2018)
30. Nomura A, "Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease", Circ Res, 121, pp.81~88 (2017)
31. Schwartz GG, "Effects of dalcetrapib in patients with a recent acute coronary syndrome", N Engl J Med, 367, pp.2089~2099 (2012)
32. Nicholls SJ, "Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol : a randomized controlled trial", JAMA, 306, pp.2099~2109 (2011)
33. Cho YK, "Implications of the dynamic nature of metabolic health status and obesity on risk of incident cardiovascular events and mortality : a nationwide population-based cohort study", Metabolism, 97, pp.50~56 (2019)
34. Cho YK, "Impact of transition in metabolic health and obesity on the incident chronic kidney disease : a nationwide cohort study", J Clin Endocrinol Metab, 105, pp.dgaa033~ (2020)
35. Cho YK, "Metabolic health is a determining factor for incident colorectal cancer in the obese population: a nationwide population-based cohort study", Cancer Med. (2020)

관련 논문AI추천